Comparison of Long-Acting Injectable (LAI) Antipsychotic Medications

First-Generation LAIs

Haloperidol Decanoate (Haldol Decanoate)

• Pharmacokinetics: 3-4 week duration; oil-based
• Administration: Deep IM injection, typically gluteal
• Dosing interval: Every 4 weeks (monthly)
• Advantages: Long clinical experience, low cost, less weight gain
• Disadvantages: Higher risk of EPS/TD, prolactin elevation, no effect on negative/cognitive symptoms
• Monitoring: AIMS, parkinsonian symptoms, akathisia, prolactin-related adverse effects

Fluphenazine Decanoate (Prolixin Decanoate)

• Pharmacokinetics: 2-3 week duration; oil-based
• Administration: Deep IM injection
• Dosing interval: Every 2-3 weeks
• Advantages: Well-established efficacy profile, low cost
• Disadvantages: High EPS rates, limited availability in some regions
• Monitoring: Similar to haloperidol decanoate

Second-Generation LAIs

Risperidone Microspheres (Risperdal Consta)

• Pharmacokinetics: Microsphere formulation, 3-week lag before therapeutic levels
• Administration: Deep IM injection, deltoid or gluteal
• Dosing interval: Every 2 weeks
• Advantages: First atypical LAI, better tolerated than FGAs
• Disadvantages: Refrigeration required, twice-monthly injections, 3-week oral supplementation needed initially
• Monitoring: Metabolic parameters, prolactin, EPS

Paliperidone Palmitate (Multiple Formulations)

• 1-month (Invega Sustenna):
  • Dosing: Monthly after loading doses
  • No oral supplementation needed
  • Deltoid or gluteal administration
• 3-month (Invega Trinza):
  • Dosing: Every 3 months (quarterly)
  • Requires stabilization on 1-month formulation first
• 6-month (Invega Hafyera/Byannli):
  • Dosing: Every 6 months
  • Requires stabilization on 1-month/3-month formulation
• Advantages: Multiple dosing intervals, no oral supplementation, no refrigeration
• Disadvantages: Prolactin elevation, limited dose adjustability with longer-acting formulations
• Monitoring: Metabolic parameters, prolactin, EPS

Aripiprazole LAIs

• Aripiprazole Monohydrate (Maintena):
  • Monthly dosing
  • 2-week oral supplementation initially
  • Lower risk of metabolic/prolactin issues
• Aripiprazole Lauroxil (Aristada):
  • Multiple dosing options: 4-week, 6-week, 8-week
  • NanoCrystal technology
• Aristada Initio:
  • One-day initiation option with oral aripiprazole
• Advantages: Favorable metabolic profile, less sedation, D2 partial agonism
• Disadvantages: Akathisia risk, may be insufficient for severe symptoms
• Monitoring: Akathisia, metabolic parameters (though lower risk)

Olanzapine Pamoate (Zyprexa Relprevv)

• Pharmacokinetics: Crystalline salt formulation
• Administration: Deep IM gluteal injection
• Dosing interval: Every 2-4 weeks
• Advantages: Similar efficacy to oral olanzapine
• Disadvantages: PDSS risk, REMS program with 3-hour monitoring, sedation, weight gain
• Monitoring: Post-injection monitoring (3 hours), metabolic parameters, sedation
• Unique feature: Only available through registered facilities with monitoring capabilities

Comparative Factors

Efficacy Rankings

• Generally similar efficacy when comparing within-molecule to oral formulations
• Clozapine > Olanzapine/Risperidone > Paliperidone > Aripiprazole > FGAs (for overall symptom control)
• Aripiprazole/FGAs > Paliperidone/Risperidone > Olanzapine (for minimizing metabolic effects)

Metabolic Profile (Best to Worst)

1. Aripiprazole LAIs
2. Haloperidol/Fluphenazine
3. Paliperidone/Risperidone LAIs
4. Olanzapine pamoate

EPS Risk (Lowest to Highest)

1. Olanzapine pamoate
2. Aripiprazole LAIs (except akathisia)
3. Paliperidone/Risperidone LAIs
4. Haloperidol/Fluphenazine decanoate

Prolactin Elevation (Lowest to Highest)

1. Aripiprazole LAIs (may reduce baseline levels)
2. Olanzapine pamoate (minimal)
3. Haloperidol decanoate
4. Risperidone/Paliperidone LAIs (significant)

Convenience Factors

• Longest interval: Paliperidone palmitate 6-month (Hafyera/Byannli)
• No oral supplementation: Paliperidone formulations, aripiprazole lauroxil with Initio
• No refrigeration needed: All except risperidone microspheres
• Most site options: Deltoid or gluteal for most (except olanzapine – gluteal only)
• Most logistically challenging: Olanzapine pamoate (REMS program requirements)

Cost Considerations (Generally)

• First-generation LAIs (lowest cost)
• Risperidone microspheres (off patent in some regions)
• Newer second-generation LAIs (highest cost)
• Olanzapine pamoate (high medication cost plus monitoring facility requirements)

The selection of an appropriate LAI should be individualized based on patient history, prior response, side effect profile, comorbidities, adherence patterns, and practical considerations like insurance coverage and injection frequency preferences.